AlphaTON Capital Corp was incorporated in Ontario in 1973. AlphaTON is a clinical-stage immuno-oncology company that believes it will be a first-in-class therapy for cancer avoidance in patients with known checkpoint resistance pathways to improve long-term treatment response and quality of life. AlphaTON is currently working on nine immuno-oncology assets, five of which are in the preclinical stage and four in the clinical stage. AlphaTON drug development pipeline products include biological-based product candidates or technologies to address known resistance pathways/mechanisms of current checkpoint inhibitors based on identified scientific principles, including intratumoral delivery, nanoparticles, liposomes, aptamers and virus-like particles.